Paul Edwards Posted March 24, 2015 Share Posted March 24, 2015 Xofigo (radium 223) has changed the treatment of prostate cancer metastatic to bone. Xofigo is chemically similar to calcium, so tissues that uptake calcium uptake radium as well. That means principally bone, especially in highly metabolically active sites like bone metastases. Lutetium-177 (Lu-177) is a radioactive substance which scientists have attached to an antibody found on the surface of at least 95 percent of prostate cancer cells and called prostate surface membrane antigen (PSMA). Unlike Xofigo, which only attaches to bone metastases, Lu-177-anti-PSMA attaches to any metastasis — bone, lymph node or visceral. It can potentially treat systemic micrometastases as well. Click on the link to read an interesting article in the New Prostate Cancer Infolink. Link to comment Share on other sites More sharing options...
Paul Edwards Posted March 24, 2015 Author Share Posted March 24, 2015 Researchers are looking at another interesting use of PSMA antibodies. Instead of linking a radioactive tracer to PSMA antibodies, the next step will be to link the PSMA antibodies to a light-emitting molecule called a fluorophore. The fluorophore will be activated at the time of surgery to light up cancer cells so the surgeon can see the extent of the cancer and can ensure that he has removed all of the cancer. The surgeon would also be able to see whether lymph nodes were affected and needed to be removed. Some amazing developments are happening in the treatment of prostate cancer! Link to comment Share on other sites More sharing options...
Paul Edwards Posted April 26, 2016 Author Share Posted April 26, 2016 There have now been further clinical trials in Germany with Lutetium-177 The New Prostate Cancer Infolink has an update, Click on this link to read the article. Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.